Curated News
By: NewsRamp Editorial Staff
June 23, 2026

Heidelberg Pharma AGM Approves All Proposals, Elects New Board Member

Discuss on Substack
Original Source

TLDR

  • Heidelberg Pharma shareholders overwhelmingly approved all agenda items, ensuring stable governance for advancing its ADC pipeline.
  • Heidelberg Pharma AG shareholders voted 98.67-98.72% to approve management proposals, elect Jack Yefei Ling to the Supervisory Board, and reduce board size.
  • Heidelberg Pharma's ATAC technology, derived from death cap mushroom, targets cancer with a novel mechanism, offering hope for patients.
  • Heidelberg Pharma uses Amanitin from the green death cap mushroom to create ADCs, a unique approach in cancer therapy.

Impact - Why it Matters

<p>This news matters because Heidelberg Pharma's unique ATAC technology, derived from a deadly mushroom toxin, represents a novel therapeutic approach for hard-to-treat cancers like multiple myeloma and Non-Hodgkin Lymphoma. The strong shareholder support and strategic board changes signal confidence in the company's direction, potentially accelerating the development of its pipeline. For patients and investors, this could mean faster progress toward new cancer treatments and increased value as the company advances its clinical programs.</p>

Summary

Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company pioneering innovative Antibody Drug Conjugates (ADCs), announced the successful outcome of its ordinary virtual Annual General Meeting held on June 23, 2026. Shareholders overwhelmingly approved all management proposals with a majority ranging between 98.67% and 98.72%. Key decisions included the formal approval of all Management Board and Supervisory Board members for the 2024/2025 financial year, the appointment of auditors for the 2025/2026 financial year, and the approval of the remuneration report for the Management Board. Notably, the meeting elected Mr. Jack Yefei Ling as a new member of the Supervisory Board and passed a resolution to amend the Articles of Association, reducing the Supervisory Board from seven to five members. Attendance, including postal votes, reached 80.55% of the current capital stock, reflecting strong shareholder engagement.

Heidelberg Pharma is at the forefront of cancer therapy development, uniquely utilizing Amanitin, a toxin derived from the green death cap mushroom, as the basis for its ATAC technology. The company's lead candidate, HDP-101 (INN: pamlectabart tismanitin), is a BCMA ATAC currently in clinical development for multiple myeloma and has received both Orphan Drug Designation and Fast Track Designation from the FDA. Additional candidates include HDP-102 for Non-Hodgkin Lymphoma, HDP-103 for metastatic castration-resistant prostate cancer, and HDP-104 targeting gastrointestinal tumors such as colorectal cancer, with the latter two having completed preclinical development and available for partnering. For more details on the Annual General Meeting, including voting results, visit the official AGM page. The company is based in Ladenburg, Germany, and listed on the Frankfurt Stock Exchange. More information is available at www.heidelberg-pharma.com.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Heidelberg Pharma AGM Approves All Proposals, Elects New Board Member

blockchain registration record for this content.